Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillermo de Velasco

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitorsGuillermo de Velasco
Lancet (London, England)|January 20, 2020
Optimising first-line treatment for metastatic renal cell carcinomaGuillermo de Velasco
Journal of Geriatric Oncology|May 18, 2023
Is immunotherapy safe and effective for older patients with kidney cancer?Filipa Carneiro, Guillermo de Velasco
European Urology|December 16, 2025
Re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4Jorge Esteban-Villarrubia, Guillermo de Velasco
Nature Reviews. Urology|April 13, 2026
Targeting metastatic bladder cancer when money is an issueJorge Esteban-Villarrubia, Guillermo de Velasco
ESMO Open|June 24, 2020
Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in SpainLuis Manso, Guillermo De Velasco, Luis Paz-Ares
Cancer Treatment Reviews|July 20, 2024
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinomaPatricia Rioja, M Rey-Cardenas, Guillermo De Velasco
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor TreatmentGuillermo de Velasco, Boonie Bermas, Toni K Choueiri
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literatureGuillermo de Velasco, Cesar Munoz, Juan M Sepulveda, et al.
Urologic Oncology|October 21, 2015
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line settingGuillermo de Velasco, Lana Hamieh, Suzanne Mickey, et al.
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitorsGuillermo de Velasco
Lancet (London, England)|January 20, 2020
Optimising first-line treatment for metastatic renal cell carcinomaGuillermo de Velasco
Journal of Geriatric Oncology|May 18, 2023
Is immunotherapy safe and effective for older patients with kidney cancer?Filipa Carneiro, Guillermo de Velasco
European Urology|December 16, 2025
Re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212-4Jorge Esteban-Villarrubia, Guillermo de Velasco
Nature Reviews. Urology|April 13, 2026
Targeting metastatic bladder cancer when money is an issueJorge Esteban-Villarrubia, Guillermo de Velasco
ESMO Open|June 24, 2020
Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in SpainLuis Manso, Guillermo De Velasco, Luis Paz-Ares
Cancer Treatment Reviews|July 20, 2024
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinomaPatricia Rioja, M Rey-Cardenas, Guillermo De Velasco
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor TreatmentGuillermo de Velasco, Boonie Bermas, Toni K Choueiri
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literatureGuillermo de Velasco, Cesar Munoz, Juan M Sepulveda, et al.
Urologic Oncology|October 21, 2015
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line settingGuillermo de Velasco, Lana Hamieh, Suzanne Mickey, et al.
Pageof 13